Accession Number: | 0001209191-21-027413 |
Date: | 2021-04-16 |
Issuer: | FIVE PRIME THERAPEUTICS, INC. (FPRX) |
Original Submission Date: |
DHINGRA KAPIL
111 OYSTER POINT BOULEVARD
SOUTH SAN FRANCISCO, CA 94080
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
STOCK OPTION (RIGHT TO BUY) | 37.99 | 2021-04-16 | deemed execution date | D | 25,000 (d) | common stock 25,000 | $37.99 | 0 | direct | |||
STOCK OPTION (RIGHT TO BUY) | 29.8 | 2021-04-16 | deemed execution date | D | 10,000 (d) | common stock 10,000 | $29.80 | 0 | direct | |||
STOCK OPTION (RIGHT TO BUY) | 17.27 | 2021-04-16 | deemed execution date | D | 10,000 (d) | common stock 10,000 | $17.27 | 0 | direct | |||
STOCK OPTION (RIGHT TO BUY) | 6.09 | 2021-04-16 | deemed execution date | D | 15,000 (d) | common stock 15,000 | $6.09 | 0 | direct | |||
STOCK OPTION (RIGHT TO BUY) | 4.14 | 2021-04-16 | deemed execution date | D | 20,000 (d) | common stock 20,000 | $4.14 | 0 | direct |
ID | footnote |
---|---|
f1 | pursuant to the agreement and plan of merger, dated march 4, 2021 (the "merger agreement"), by and among the five prime therapeutics, inc. (the "company"), amgen inc. ("parent") and franklin acquisition sub, inc., a wholly owned subsidiary of parent ("purchaser"), purchaser merged with and into the company, with the company surviving as a wholly owned subsidiary of parent (the "merger"), effective as of april 16, 2021. pursuant to the merger agreement, immediately prior to the effective time of the merger, each option to purchase shares of common stock of the company, par value $0.001 per share ("common stock"), granted by the company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such option multiplied by (y) the excess, if any, of (a) $38.00 minus (b) the exercise price payable per share under such option. |
f2 | not applicable. |